Abstract
Current drug discovery platforms have proven incapable of supplying enough new antibiotic types to meet the challenge of rapidly developing clinical resistances. New techniques that specifically incorporate potential resistance adaptations during design are necessary. In cases of known specific resistance mechanisms, a biophysical approach may allow rational development of existing drugs that escape resistance. In this work, we use deep mutational scanning (DMS), a next-generation sequencing-based technique that reports on the site-specific fitness effects of mutations across an entire protein, to investigate the contribution of Virginiamycin acetyltransferase (VatD) to several streptogramin analogues.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
